Clinical trial
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic…
NCT00004095 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00004095 |
|---|---|
| Title | Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors |
| Official title | Phase I Trial of Irinotecan (CPT-11) and Gemcitabine in Patients With Solid Tumors |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, irinotecan hydrochloride |
| Enrollment | 38 |
| Start date | Aug 1, 1999 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | May 7, 2003 |
| Last update posted | Apr 18, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: